Histone deacetylase inhibitors impair the host immune response against Mycobacterium tuberculosis infection
C Zhu, Y Cai, J Zhu, L Zhang, A Xing, L Pan, H Jia… - Tuberculosis, 2019 - Elsevier
Histone deacetylase inhibitors (HDACi), a novel class of anti-cancer drug, have been
recently reported to suppress host immunity and increase susceptibility to infection.
Tuberculosis, a leading infectious disease killer caused by Mycobacterium tuberculosis (M.
tb), is basically the product of the interaction between bacterial virulence and host
resistance. However, the effects of HDACi in host immunity against M. tb is largely unknown.
In this study, we found that HDACi including Trichostatin A (TSA) and suberoylanilide …
recently reported to suppress host immunity and increase susceptibility to infection.
Tuberculosis, a leading infectious disease killer caused by Mycobacterium tuberculosis (M.
tb), is basically the product of the interaction between bacterial virulence and host
resistance. However, the effects of HDACi in host immunity against M. tb is largely unknown.
In this study, we found that HDACi including Trichostatin A (TSA) and suberoylanilide …